Novel Treatment Strategies in IgE-Mediated Allergy
June 4, 2002
As President-Elect of the World Allergy Organization-IAACI (WAO), it is my pleasure to bring you the 19th symposium in a series of World Allergy Forums presenting state-of-the-art programs at major allergy conventions around the world.
WAO is the rapidly expanding global umbrella organization representing 61 national and regional allergy and clinical immunology societies. A major role of WAO is the development of educational programs in allergy and clinical immunology for our member societies, and for outreach presentations to professional medical organizations that have a strong interface with our specialty.
WAO is recognized by World Health Organization to be the major global voice of allergy. The importance of allergen exposure and immunological sensitization to the development of asthma, has led to a collaboration between WAO and WHO on a WHO Technical Document, Prevention of Allergy and Asthma. Against this background of increasing global awareness of the role of atopy in the development of asthma, "Novel Treatment Strategies in IgE-Mediated Allergy" is an important addition to the WAO educational portfolio. I sincerely thank the European Academy of Allergology and Clinical Immunology for enabling us to bring this program to you.
I hope you will enjoy this symposium and the presentations of our excellent faculty.
President-elect, World Allergy Organization-IAACI
June 4, 2002
On behalf of the World Allergy Organization-IAACI (WAO), it is a great pleasure to welcome you to this World Allergy Forum symposium, during which internationally renowned speakers will address Novel Treatment Strategies in IgE-Mediated Allergy.
Allergists have long known that IgE-mediated allergy is important in many asthmatics, as well as critical in the causation of allergic rhinitis, food allergy, allergic eczema and anaphylaxis. Our faculty will review four major therapeutic modalities that target the underlying pathology of allergic disease.
While new therapies are in development, work continues into the mode of action of the anti-mediator therapies that continue to make such a major contribution to the treatment of our patients. New findings on histamine receptors explain the anti-inflammatory role of antihistamines, and suggest that these agents may have an important prophylactic role.
Looking into the future, cytokine receptor antagonist therapy is presently being evaluated, and indications are that this form of therapy, either alone or in combination with other therapies, may be of value in the treatment of IgE-mediated allergic diseases.
Few advances in our field of medicine have caused as much excitement as the advent of the availability of anti-IgE as a therapeutic tool in the treatment of allergic diseases. The ability to reduce circulating IgE with a monoclonal antibody, with the consequent reduction in cell-bound IgE and mast-cell degranulation, has been shown to reduce the need for topical and systemic corticosteroids in asthma and allergic rhinitis, and to prevent exacerbations of asthma.
Immunotherapy aims to interfere with the underlying pathophysiologic mechanisms involved in allergic disease, and to change the natural outcome of allergic sensitization. The risk of inducing anaphylaxis with injection immunotherapy has led to a number of developments in the molecules to be administered, and in the modes of administration.
We look forward to four excellent lectures, and to lively interaction with you during the discussion period that will follow.
WAO sincerely acknowledges the unrestricted educational grant provided by Novartis and Genentech to facilitate this event.
Paul van Cauwenberge
President, European Academy of Allergology and Clinical Immunology